Dapagliflozin is not only clinically effective, but also cost-effective in patients with chronic kidney disease
The burden of chronic kidney disease (CKD) to both health care systems and patients is considerable. Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, has been shown to be an efficacious treatment for CKD in the ...
Nov 2, 2022
0
2